Literature DB >> 25098216

[Prevalence of metabolic syndrome in patients with psoriasis].

Claudia Jessica Espinoza Hernández1, Rosa María Lacy Niebla1, María Elena Soto López2, Nicole Stephanie Kresch Tronik1, María Elisa Vega-Memije1.   

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory disease associated with increased cardiovascular risk. Metabolic syndrome (MS) is a significant predictor of cardiovascular events.
OBJECTIVE: To assess the prevalence of MS in a Mexican population with psoriasis.
METHODS: A descriptive, case control study was performed, involving a series of 209 patients. Relevant demographic, clinical, anthropometric, and analytic information was obtained from all participants. Metabolic syndrome was diagnosed according to the NCEP-ATPIII criteria.
RESULTS: The study included 103 patients with psoriasis and 106 controls. The mean age of the case patients was 48.37 years; 55% were women and 46% were men. Metabolic syndrome was significantly more common in psoriatic patients than in controls (41.7 vs. 20%, odds ratio: 1.738; 95% CI: 1.194-2.531; p < 0.001). We also found a higher frequency of diabetes mellitus (17.3 vs. 6.6%; p = 0.001), alcoholic habits (8.7 vs. 0.9%; p = 0.009), and higher levels of blood pressure (p = 0.002), BMI (p = 0.016), waist circumference (p = 0.008), and triglycerides (p = 0.002).
CONCLUSIONS: Psoriatic patients have a higher prevalence of metabolic syndrome, which can favor cardiovascular events.

Entities:  

Mesh:

Year:  2014        PMID: 25098216

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  2 in total

1.  Carotid intima-media thickness in patients with psoriasis with and without metabolic syndrome.

Authors:  Ana L Ramírez-Terán; María E Vega-Memije; Margarita Torres-Tamayo; María R Martínez-Alvarado
Journal:  Arch Cardiol Mex       Date:  2022-07-01

2.  Metabolic Syndrome and Psoriasis: A Case-Control Study in Kabul, Afghanistan.

Authors:  Ahmad Khalid Aalemi; Mohammad Barin Bahain; Abdul Ghafar Hamdard
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-30       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.